CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin) Dosage Guide, Benefits & Side Effects
This GHRH plus ghrelin-agonist blend amplifies pulsatile GH release for fat loss, muscle repair, and deep sleep without raising cortisol.
Chemical Makeup
2
Amino Acids
CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin)
Asn
Position 1
Ala
Position 2
As seen on
CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin) Dosage Guide for Fat Loss / MuscleCJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin) Dosage Calculator
This combines CJC-1295 (No DAC) with Ipamorelin to boost growth hormone release, typically taken two to three times a day.
Vial size
10 mg
Bacteriostatic water
2 mL
Dosing
300 mcg each
Frequency
1–3×/day
Cycle
12–24 weeks
Benefit
Fat Loss / Muscle
What is CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin)?
This is a combination of two peptides, CJC-1295 (No DAC) and Ipamorelin, that work together through two different pathways to boost the body's natural growth hormone release. CJC-1295 extends each hormone 'pulse,' while Ipamorelin triggers a clean, targeted pulse without raising stress hormones. Together, they're commonly used in research and wellness settings for muscle preservation, fat loss, better sleep, and recovery.
Weight
Research targets include appetite regulation, fat metabolism, and body composition.
Growth
Research targets include growth hormone signaling, IGF-1 pathways, and tissue development.
cjci
Is CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin) FDA approved?
CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin) is not an FDA-approved drug. It is intended for research purposes only and is not approved for human consumption, diagnostic, or therapeutic use.
Research Use Only
CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin) has not been evaluated by the FDA for safety or efficacy in humans.
No Clinical Oversight
Not manufactured under FDA-regulated quality or clinical standards.
Unregulated Sourcing
Purity, dosing, and sourcing are not verified through FDA testing or oversight.
Our top-rated vendor
View all vendors
Our rankings are based solely on third-party lab testing rigor, COA transparency, and pricing — no paid placements, no affiliate influence. We update this list as new data comes in.
Based on current scores, this vendor ranks highest across those criteria.
Protide Health
#1 Rated Research Peptide Supplier
How Does CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin) Work?
One part of this combo (CJC-1295) binds a pituitary receptor to stretch out and strengthen each natural pulse of growth hormone; the other part (Ipamorelin) mimics the 'hunger hormone' ghrelin to trigger a separate, clean pulse of its own. Used together, the two pulses combine for a much bigger release than either could produce alone.
Stretches each GH pulse
CJC-1295 lengthens and strengthens the pituitary's natural growth hormone pulses.
Adds a second trigger
Ipamorelin mimics the 'hunger hormone' to spark its own separate pulse.
Combined effect is bigger
The two pulses stack for a release larger than either alone.
CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin) Targeted areas
How to reconstitute CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin)
The materials you'll need and step-by-step instructions for safely mixing CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin) with bacteriostatic water.
Materials needed
Your CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin) vial (lyophilized)
Alcohol swabs
Bacteriostatic sterile water
3 mL syringes (Luer Lock tip)
25G or 27G needles (Luer Lock). Other gauges may also be acceptable.
Sharps container (optional)
Remove the caps
Sanitize the rubber stoppers
Attach the needle
Draw the bac water
Pull back on the plunger to draw your desired volume of bacteriostatic water. If you overfill, just push the excess back in until you reach the right marker on the syringe.
Insert the needle into the CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin) vial
With the bac water in your syringe, insert the needle into the CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin) vial at a slight angle to avoid pressure buildup.
Release the water gently
Let the water run gently down the side of the vial. Don't inject it forcefully.
Swirl to dissolve
Avoid shaking. Gently swirl, flip, and roll the vial to dissolve the powder.
Check for full dissolution
Cap, dispose, and store
How to Store CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin)
Freeze the dry powder for up to 2–3 years. Once mixed with liquid, refrigerate and use within about a month, and avoid freezing it again.
Lyophilized Storage
Store at -20°C for up to 24–36 months.
Reconstituted Storage
With bacteriostatic water, refrigerate at 2–8°C and use within 28 days.
Handling Notes
Do not freeze the reconstituted solution.
What Are the Benefits of CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin)?
What research says it may help with, and how it works in the body.
muscle growth
Raising growth hormone levels helps the body build muscle protein and hold on to nitrogen, a sign the body is using protein to build tissue rather than break it down, during training.
Keeping growth hormone elevated over time may help muscles repair faster between workouts.
Optimizing growth hormone levels helps preserve muscle when eating fewer calories or as part of the aging process.
metabolic health
Improved growth hormone patterns may help the body use sugar and fat for energy more efficiently.
Growth hormone helps the body break down stored fat for fuel while also helping preserve lean muscle tissue.
antiaging
Growth hormone levels that peak in the evening line up with deeper, more restful sleep.
Keeping growth hormone elevated over time supports skin elasticity and the health of connective tissue.
recovery
Growth hormone helps tissue repair itself and supports recovery after exercise or injury.
Boosts the body's production of collagen, which helps keep joints and connective tissue strong and intact.
What Are the Side Effects of CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin)?
Who should avoid it, warning signs to watch for, and what to know before combining it with other compounds.
Who Should Avoid It
Cancer history or active malignancy
Severe diabetes requiring tight glucose control
Carpal tunnel syndrome or nerve compression disorders
Stop Right Away If You Notice
Persistent joint pain or swelling indicating fluid retention
Significant blood glucose changes or diabetic control issues
Unusual fatigue, lethargy, or mood deterioration
Injection site infections or persistent reactions
Numbness or tingling in hands/feet
Signs of accelerated tumor growth if cancer history exists
Milder Signs to Watch For
CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin) contains these peptides
The individual peptides blended together to make CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin).
cjc
CJC-1295 (without DAC)
Phase 2
ipa
Ipamorelin
How Long Should a CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin) Cycle Last?
This breaks down how long a typical CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin) cycle runs and what research suggests happens at each stage. Research shows that staying on a peptide continuously, without a break, may make it less effective over time.
That's why most research protocols build in a break between cycles, often called a washout period, to let the body reset before starting again.
Related peptides
aod
Metabolic
AOD-9604
Experimental
adi
Adipotide
Phase 1
bam
BAM-15
Preclinical
cag
Cagrilintide
Phase 3
Cheat Sheets Featuring CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin)
See how CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin) fits into a broader research stack with these free downloadable cheat sheets. Each one includes reference dose ranges, dosing frequency, and half-life for every peptide it covers. For research purposes only.
13 peptides
78 peptides
19 peptides
Browse user-created protocols
Real protocols from the community that include CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin)
Morning Daily
John
GLP-3
Longevity
mot
CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin) Research References
It is an experimental compound
CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin) is an experimental compound
2-10 fold GH increase, 1.5-3 fold IGF-1 increase with 5.8-8.1 day half-life.
2006
First selective GHS with no ACTH/cortisol effects even at 200x effective dose.
1998
CJC-1295 preserves pulsatile GH secretion while increasing basal levels 7.5-fold.
Cellular study demonstrating potentiation of GHRH signaling with GHS receptors present.
2002
Frequently Asked Questions About CJC-1295/Ipamorelin Blend (CJC-1295 (without DAC), Ipamorelin)
Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.
What is CJC-1295 (No DAC)/Ipamorelin and how does the combination work?
This is a blend of two growth hormone secretagogues that are typically used together. CJC-1295 without DAC (also called Mod GRF 1-29) is a growth hormone-releasing hormone (GHRH) analog, while Ipamorelin is a selective ghrelin receptor agonist (a growth hormone-releasing peptide, or GHRP). Because they act on different receptors, they are often described as working synergistically to produce a stronger pulse of endogenous growth hormone release than either compound alone, while Ipamorelin's selectivity means it does not meaningfully raise cortisol, prolactin, or appetite the way some older GHRPs do. In the U.S., neither peptide is FDA-approved for human use, and material sold online is generally labeled 'for research use only.'
How does CJC-1295 (No DAC) differ from CJC-1295 with DAC?
The 'No DAC' version lacks the Drug Affinity Complex modification, giving it a short half-life of roughly 30 minutes, compared to about 6–8 days for the DAC version. This means No DAC CJC-1295 produces a sharper, more transient GH pulse and is typically dosed daily (sometimes multiple times per day), whereas DAC versions are dosed less frequently (e.g., weekly) because they stay active in the body much longer. Users and sources report that the DAC form is more associated with water retention and tingling/numbness sensations, while the No DAC form is generally described as having a milder side-effect profile.
What dosage and injection frequency are commonly discussed?
Commonly discussed research protocols use roughly 100–300 mcg of each peptide (CJC-1295 No DAC and Ipamorelin) per subcutaneous injection, often starting around 100 mcg of each and titrating upward every 1–2 weeks. Because CJC-1295 No DAC clears quickly (~30 minutes) and Ipamorelin has a short half-life of about 2 hours, protocols typically call for daily dosing, sometimes once at bedtime and/or upon waking, timed on an empty stomach (30–60 minutes before food) to align with natural GH pulses. These figures come from vendor and clinic guides rather than an approved clinical dosing standard, and actual practices vary widely.
How long are typical cycles, and is a break needed between them?
Many protocols described online use 8–12 week cycles followed by a break of about 4 weeks, the rationale given being to help preserve receptor sensitivity over time. There is no standardized, regulator-reviewed cycle length, so these figures reflect common practice in enthusiast and compounding-clinic literature rather than an established clinical guideline.
What side effects are commonly reported?
Frequently reported effects include injection-site reactions (redness, swelling, or soreness), transient flushing or warmth, mild headache, temporary fatigue, and some water retention or puffiness, especially early in use. These are generally described as mild and as diminishing within the first 1–4 weeks. Because Ipamorelin is selective for the ghrelin receptor, it is reported to avoid the larger cortisol/prolactin increases and appetite spikes associated with older, less-selective GHRPs. These reports come from user and clinic sources rather than controlled human safety trials, so the full risk profile of this specific unapproved combination has not been formally established.
How should the peptide blend be reconstituted and stored?
General guidance describes reconstituting lyophilized (freeze-dried) peptide powder with bacteriostatic water injected slowly down the inside wall of the vial to avoid foaming/damaging the peptide, then gently swirling (not shaking) to dissolve. Unreconstituted vials are commonly stored frozen or refrigerated and are said to remain stable for roughly 1–2 years; once reconstituted, the solution is typically kept refrigerated (about 2–8°C) and used within roughly 30–45 days, avoiding repeated freeze-thaw cycles. Exact stability depends on the specific product and manufacturer instructions, which should take precedence over general guidance.
Is CJC-1295/Ipamorelin legal to obtain, and is it FDA-approved?
No FDA-approved drug product exists under this name. Both CJC-1295 and Ipamorelin are unapproved investigational compounds. As of late 2024/2026 reporting, the FDA's Pharmacy Compounding Advisory Committee voted against including either peptide on the list that would allow 503A pharmacy compounding, meaning there is currently no recognized U.S. compounding pathway for them. Consequently, most supply is sold as 'research chemical' product not intended for human consumption, and purity, sterility, and labeled content are not independently verified or regulated the way an approved drug would be. Buyers should treat any human-use claims from such sellers with caution.
What is this peptide combination commonly claimed to be used for?
Online sources and clinics commonly associate this combination with goals such as increased lean muscle mass, reduced body fat, improved sleep quality, and general anti-aging or recovery support, based on its role in stimulating endogenous growth hormone release. These are claims made by vendors, clinics, and user communities rather than findings from large, controlled clinical trials in the approved-drug sense, and the compound is not approved by regulators for any of these uses in humans.